Wall Street analysts predict that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will announce earnings per share of ($0.57) for the current quarter, Zacks reports. Two analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.59). Bellicum Pharmaceuticals posted earnings of ($0.71) per share during the same quarter last year, which would indicate a positive year over year growth rate of 19.7%. The company is expected to announce its next earnings results on Tuesday, November 6th.
On average, analysts expect that Bellicum Pharmaceuticals will report full year earnings of ($2.37) per share for the current fiscal year, with EPS estimates ranging from ($2.46) to ($2.26). For the next financial year, analysts forecast that the firm will report earnings of ($2.22) per share, with EPS estimates ranging from ($2.45) to ($2.03). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.05). The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.08 million.
In other news, insider David M. Spencer sold 40,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Wednesday, July 18th. The stock was sold at an average price of $7.63, for a total transaction of $305,200.00. Following the completion of the transaction, the insider now directly owns 99,939 shares in the company, valued at approximately $762,534.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $7.04, for a total value of $70,400.00. Following the transaction, the chief technology officer now owns 89,939 shares of the company’s stock, valued at $633,170.56. The disclosure for this sale can be found here. 9.84% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its stake in shares of Bellicum Pharmaceuticals by 161.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,949 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 10,466 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Bellicum Pharmaceuticals by 52.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 18,888 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 6,530 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Bellicum Pharmaceuticals during the 1st quarter worth approximately $170,000. DAFNA Capital Management LLC bought a new position in shares of Bellicum Pharmaceuticals during the 2nd quarter worth approximately $221,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Bellicum Pharmaceuticals during the 2nd quarter worth approximately $379,000. Institutional investors own 59.43% of the company’s stock.
Shares of NASDAQ:BLCM traded up $0.16 during trading on Friday, hitting $6.32. 235,032 shares of the company were exchanged, compared to its average volume of 343,698. The firm has a market capitalization of $267.03 million, a price-to-earnings ratio of -2.23 and a beta of 0.54. Bellicum Pharmaceuticals has a fifty-two week low of $5.02 and a fifty-two week high of $13.30. The company has a quick ratio of 10.24, a current ratio of 10.24 and a debt-to-equity ratio of 0.32.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Featured Article: How to Profit and Limit Losses With Stop Orders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.